Opendata, web and dolomites

REVERSEAUTISM SIGNED

Probing the Reversibility of Autism Spectrum Disorders by Employing in vivo and in vitro Models

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REVERSEAUTISM project word cloud

Explore the words cloud of the REVERSEAUTISM project. It provides you a very rough idea of what is the project "REVERSEAUTISM" about.

mutations    employ    individuals    branched    al    bcaas    dehydrogenase    neurological    cell    human    classified    social    molecular    ketoacid    critical    shown    prompt    treat    bckdk    functionally    amino    pathology    ing    suggests    cerebral    cognition    biomarkers    homogenous    flux    slc7a5    kinase    brain    autism    genes    potentially    forms    organoids    possibility    trial    caused    levels    group    nature    heterogeneity    employed    blood    reinforces    skills    consequence    outcome    spectrum    serum    etiological    behaviours    preventable    novarino    stereotypical    science    transporter    therapeutic    irreversible    acids    reverse    asd    disorders    elucidating    barrier    atypically    employing    communication    implying    biological    defects    form    stem    neural    genetic    poor    2014    metabolism    broad    repetitive    basis    et    clinical    neurodevelopmental    strategies    link    bcaa    2012    impairments    symptoms    exploring    converge    untangling    exome    encoding    chain    hyper    genetically    maturation    interaction    sequencing    causes    circuits    direct    molecules    mediating    reversible    gene   

Project "REVERSEAUTISM" data sheet

The following table provides information about the project.

Coordinator
INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA 

Organization address
address: Am Campus 1
city: KLOSTERNEUBURG
postcode: 3400
website: www.ist.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 1˙498˙394 €
 EC max contribution 1˙498˙394 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA AT (KLOSTERNEUBURG) coordinator 1˙498˙394.00

Map

 Project objective

Autism Spectrum Disorders (ASD) are a group of neurological conditions characterized by stereotypical or repetitive behaviours as well as impairments in social interaction and communication skills, often of genetic basis. ASD have been classified as neurodevelopmental disorders, implying irreversible defects in the maturation of neural circuits. We have shown that mutations in the Branched Chain Ketoacid Dehydrogenase Kinase (BCKDK) gene lead to a potentially preventable and reversible form of ASD (Novarino et al. Science 2012). The most direct consequence of BCKDK mutations is a hyper-metabolism of the branched chain amino acids (BCAAs), resulting in atypically low levels of serum and brain BCAAs. Recently, using whole exome sequencing we identified individuals with ASD carrying mutations in the gene SLC7A5, encoding for the transporter mediating BCAA flux across the blood brain barrier. This suggests that the BCAAs are critical for brain development and cognition and reinforces their link with ASD. The simple nature and availability of the BCAAs prompt raising the possibility that this group of amino acids may be employed to treat symptoms of other ASD. We aim at 1) elucidating the link between BCAAs, ASD, brain development and cognition; 2) exploring the possibility of employing the BCAAs to reverse symptoms caused by mutations of ASD-genes. The genetic analysis of ASD is untangling the etiological heterogeneity that may contribute to poor clinical trial outcome. However, recent studies, including our own (Novarino et al. Science 2014), show that genetic causes of neurological disorders converge along specific biological processes. Our third objective is to employ stem cell-derived human cerebral organoids to identify key molecular changes involved in the pathology of genetically distinct but functionally homogenous forms of ASD. These molecules may represent the target for future “broad spectrum” therapeutic strategies as well as potential biomarkers (aim 3).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REVERSEAUTISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REVERSEAUTISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More